Dietary modification dampens liver inflammation and fibrosis in obesity-related fatty liver disease

Obesity

Volumn 21, Issue 6, 2013, Pages 1189-1199

  Larter, Claire Z ^a   Yeh, Matthew M ^b   Haigh, W Geoffrey ^c   Van Rooyen, Derrick M ^a   Brooling, John ^a   Heydet, Deborah ^a   Nolan, Christopher J ^d   Teoh, Narci C ^a   Farrell, Geoffrey C ^a  

^a The Australian National University   (Australia)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^c VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^d CANBERRA HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALANINE AMINOTRANSFERASE; CD36 ANTIGEN; CHOLESTEROL ESTER; FATTY ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRIACYLGLYCEROL; UNCOUPLING PROTEIN 2;

ADIPOSE TISSUE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ACTIVITY; FATTY ACID OXIDATION; FEMALE; FOOD COMPOSITION; HEPATITIS; HEPATOMEGALY; LIPID DIET; LIPID LIVER LEVEL; LIPOGENESIS; LIVER FIBROSIS; MACROPHAGE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PATHOGENESIS; PROTEIN EXPRESSION; SCORING SYSTEM; STELLATE CELL; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION;

MUS;

EID: 84881375574     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.20123     Document Type: Article

References (38)

1. Larter CZ, Chitturi S, Heydet D, Farrell GC,. A fresh look at NASH pathogenesis. Part 1: the metabolic movers. J Gastroenterol Hepatol 2010; 25: 672-690.
2. Neuschwander-Tetri BA,. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 2010; 52: 774-788.
3. Farrell GC, Larter CZ,. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43: S99-S112.
4. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-923.
5. dela Peña A, Leclercq I, Field J, George J, Jones B, Farrell G,. NF-κB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. Gastroenterology 2005; 129: 1663-1674.
6. Deng Q, She H, Cheng JH, et al. Steatohepatitis induced by intragastric overfeeding in mice. Hepatology 2005; 42: 905-914.
7. Targher G, Bertolini L, Rodella S, et al. Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease. Clin Endocrinol 2006; 64: 679-683.
8. Ribeiro PS, Cortez-Pinto H, Sola S, et al. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol 2004; 99: 1708-1717.
9. Larter CZ, Yeh MM,. Animal models of NASH: getting both pathology and metabolic context right. J Gastroenterol Hepatol 2008;23:1635 - 1648.
10. Larter CZ, Yeh MM, Van Rooyen DM, et al. Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice. J Gastroenterol Hepatol 2009; 24: 1658-1668.
11. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ,. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005; 115: 1343-1351.
12. Arsov T, Silva DG, O'Bryan MK, et al. Fat aussie-a new Alström syndrome mouse showing a critical role for ALMS1 in obesity, diabetes and spermatogenesis. Mol Endocrinol 2006; 20: 1610-1622.
13. Arsov T, Larter CZ, Nolan CJ, et al. Adaptive failure to high-fat diet characterizes steatohepatitis in Alms1 mutant mice. Biochem Biophys Res Commun 2006; 342: 1152-1159.
14. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321.
15. Larter CZ, Yeh MM, Van Rooyen DM, Brooling J, Ghatora K, Farrell GC,. The PPAR-alpha agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with NASH. J Gastroenterol Hepatol 2012; 27: 341-350.
16. dela Pena A, Leclercq IA, Williams J, Farrell GC,. NADPH oxidase is not an essential mediator of oxidative stress or liver injury in murine MCD diet-induced steatohepatitis. J Hepatol 2007; 46: 304-313.
17. Ip E, Farrell GC, Hall P, Robertson G, Leclercq I,. Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology 2004; 39: 1286-1296.
18. Larter CZ, Yeh MM, Haigh WG, et al. Hepatic free fatty acids accumulate in experimental steatohepatitis: role of adaptive pathways. J Hepatol 2008; 48: 638-647.
19. Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA,. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 2011; 53: 810-820.
20. Lemasters JJ,. Dying a thousand deaths: redundant pathways from different organelles to apoptosis and necrosis. Gastroenterology 2005; 129: 351-360.
21. Cortez-Pinto H, Chatham J, Chacko VP, Arnold C, Rashid A, Diehl AM,. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA 1999; 282: 1659-1664.
22. Feldstein AE, Canbay A, Angulo P, et al. Hepatocyte apoptosis and Fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003; 125: 437-443.
23. Alkhouri N, Dixon LJ, Feldstein AE,. Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal. Expert Rev Gastroenterol Hepatol 2009; 3: 445-451.
24. Carter-Kent C, Zein NN, Feldstein AE,. Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment. Am J Gastroenterol 2008; 103: 1036-1042.
25. Bieghs V, Wouters K, van Gorp PJ, et al. Role of scavenger receptor A and CD36 in diet-induced nonalcoholic steatohepatitis in hyperlipidemic mice. Gastroenterology 2010; 138: 2477-2486.
26. Kim JY, van de Wall E, Laplante M, et al. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest 2007; 117: 2621-2637.
27. Lanthier N, Molendi-Coste O, Cani PD, van Rooijen N, Horsmans Y, Leclercq IA,. Kupffer cell depletion prevents but has no therapeutic effect on metabolic and inflammatory changes induced by a high-fat diet. FASEB J 2011;25:4301 - 4311.
28. Stanton MC, Chen SC, Jackson JV, et al. Inflammatory signals shift from adipose to liver during high fat feeding and influence the development of steatohepatitis in mice. J Inflamm (Lond) 2011; 8: 8.
29. Gentile CL, Pagliassotti MJ,. The role of fatty acids in the development and progression of nonalcoholic fatty liver disease. J Nutr Biochem 2008; 19: 567-576.
30. Bass NM, Merriman RB,. Fatty acid metabolism and lipotoxicity in the pathogenesis of NASH. In:, Farrell GC, George J, Hall P, McCullough AJ, (eds). Non-Alcoholic Steatohepatitis. Oxford: Blackwell Publishing; 2005. pp 109-122.
31. Puri P, Baillie RA, Wiest MM, et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007; 46: 1081-1090.
32. Van Rooyen DM, Larter CZ, Haigh WG, et al. Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis. Gastroenterology 2011; 141: 1393-1403.
33. Wouters K, van Bilsen M, van Gorp PJ, et al. Intrahepatic cholesterol influences progression, inhibition and reversal of non-alcoholic steatohepatitis in hyperlipidemic mice. FEBS Lett 2010; 584: 1001-1005.
34. Mari M, Caballero F, Colell A, et al. Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. Cell Metab 2006; 4: 185-198.
35. Canbay A, Taimr P, Torok N, Higuchi H, Friedman S, Gores GJ,. Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest 2003; 83: 655-663.
36. Duffield JS, Forbes SJ, Constandinou CM, et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 2005; 115: 56-65.
37. Liu X, Lazenby AJ, Clements RH, Jhala N, Abrams GA,. Resolution of nonalcoholic steatohepatits after gastric bypass surgery. Obes Surg 2007; 17: 486-492.
38. Ding XD, Saxena NK, Lin S, Xu A, Srinivasan S, Anania FA,. The roles of leptin and adiponectin: a novel paradigm in adipocytokine regulation of liver fibrosis and stellate biology. Am J Pathol 2005; 166: 1655-1669.